1. Introduction {#sec1}
===============

Early administration of broad-spectrum, empiric antimicrobial therapy reduces mortality and improves outcomes in patients with severe sepsis and septic shock. However, broad-spectrum therapy favors the emergence of drug-resistance and adds excessively to the costs of care.*Deescalation* refers to a strategy whereby clinicians either discontinue or change to a narrower spectrum antimicrobial drug and is usually carried out after culture results become available. The objective of this study was to identify variables associated with deescalation failure.

2. Methods {#sec2}
==========

This study is reported following the STROBE statement checklist for observational studies \[[@B1]\].

2.1. Ethics, Consent, and Permissions {#sec2.1}
-------------------------------------

The institutional Office of Research Affairs (ORA) and ORA Research Ethics Committee approved the study methods (RAC number 2131108). The Research Ethics Committee waived patient consent based on the study design. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. No individual patient data is presented.

2.2. Study Design and Setting {#sec2.2}
-----------------------------

In this prospective, cohort study we reviewed consecutive adult (\>14 years) patients admitted to the intensive care unit (ICU) with a diagnosis of sepsis or septic shock. The period of study was from 1st January 2013 to 1st January 2014. Patients who were not for resuscitation (DNR) or were expected to die within 48 hours were excluded.

2.3. Operational Definitions {#sec2.3}
----------------------------

Antibiotic therapy was considered appropriate based on in vitro sensitivity on culture. On day 7 after ICU admission, we categorized patients into four groups based on antibiotic administration:*no change* in antibiotics,*deescalation* (defined as stopping or changing to a narrower spectrum antibiotic),*escalation* (where antibiotics were changed to those with a broader spectrum of antimicrobial coverage), or*mixed changes* (where both escalation to a broader spectrum of coverage and discontinuation of antibiotics were carried out).

2.4. Statistical Analysis {#sec2.4}
-------------------------

Continuous data was tested for normality; measures of central tendency were reported as means ± standard deviations (SD) and compared using Student\'s *t*-test for normally distributed variables and reported as medians (interquartile range, IQR) and compared using the Mann-Whitney *U* test for skewed data. Categorical variables were compared using the *χ* ^2^ test or the Fisher Exact test for *n* \< 5. Logistic regression analysis was performed to determine the predictive ability of variables for antibiotic deescalation. Univariate and multivariate techniques were used, and, for multivariate regression, a backward mode with a threshold 0.10 was used for elimination. Multivariate associations were reported as odds ratios, Exp(*B*) with 95% confidence intervals. A two-sided *p* value of \< 0.05 was considered as statistically significant. All analyses were carried out using IBM SPSS version 22.0.

3. Results {#sec3}
==========

Three hundred and ninety-five patients were included in the study; 194 (49%) were female, mean age of 52.4 ± 12 years; mean APACHE II and SAPS II scores were 24 ± 7.8 and 45 ± 19.7. Three hundred and thirty-three (84.3%) patients were admitted from within the hospital, 58 (14.7%) were admitted from the emergency department, and 4 (1%) came as interhospital transfers via MEDEVAC. Two hundred and forty-eight patients (62.8%) were admitted after regular working hours (4:30 pm to 7:30 am); of these, 214 (86%) came from in-hospital wards, 30 (12%) from the emergency department, and 4 (2%) as transfers. Only 195 (49.3%) of the total 395 patients had positive cultures. Nosocomial acquisition of sepsis was confirmed in 105 \[75%\] of 139 culture-positive patients admitted "after-hours" and in 50 \[89%\] inpatients of 56 culture-positive patients admitted during "regular" hours. Patients with hematologic malignancy comprised 106 (26.8%) of the admissions; detailed patient characteristics are shown in [Table 1](#tab1){ref-type="table"}.

Empiric antibiotics were a combination of vancomycin, 292 patients (74%), and carbapenem, 277 patients (70%), with colistin, 70 patients (18%), aminoglycosides, 37 (9%), and quinolones, 64 (16%), used in addition. Empiric caspofungin was added in 47 (12%) patients. Most frequent empiric antibiotic regimen used was vancomycin + carbapenem, 193 (49%), followed by vancomycin + extended-spectrum penicillin/*β*-lactamase inhibitor, 131 (33%), and vancomycin and aminoglycosides or quinolones, 71 (18%). Cultures were positive in 195 (49.4%) patients and 200 (50.6%) remained culture negative.

Please refer to [Table 2](#tab2){ref-type="table"} for frequencies of all isolates.

Empiric therapy was*appropriate* in 57% cases. The median ICU length of stay was 6 days (IQR 4--43) with a 28-day survival rate of 71% (281 patients).

Antimicrobial deescalation was carried out in 189 (48%) patients; in 156 (39%) patients no changes in the antimicrobial regimen were made; 42 (11%) patients had their antimicrobial coverage escalated and in 8 (2%) patients mixed changes were made.

Please refer to [Table 3](#tab3){ref-type="table"} for differences in patient characteristics by final antibiotic grouping.

In a comparison of patients that were deescalated compared to patients "not deescalated" (combination of groups with escalation, no changes, or both escalation and deescalation, i.e., mixed changes), rates of malignancy, multidrug resistant (MDR) organisms, fungal sepsis, chronic organ failure (renal, liver), baseline APACHE II, SAPS II, and serum procalcitonin were significantly different. Deescalation rates were not significantly different between patients with positive cultures and those with negative cultures or single versus multiple positive culture sites or when the patient continued to be vasopressor-dependent. Deescalation was associated with a significantly lower ICU mortality compared to patients not deescalated, 27 out of 188 patients (14.3%) versus 47 out of 207 patients (22.7%).

3.1. Univariate Outcome Data {#sec3.1}
----------------------------

On univariate regression analysis*failure to deescalate* was significantly predicted by APACHE II and SAPS II scores, OR 1.02 (95% CI 1.002--1.05, *p* = 0.037) and OR 1.01 (95% CI 1.005--1.02, *p* = 0.004), baseline serum procalcitonin OR 1.01 (95% CI 1.003--1.016, *p* = 0.003), hematologic malignancy OR 2.85 (95% CI 1.3--6.2, *p* = 0.009), isolation of MDR organisms OR 2.39 (95% CI 1.18--4.8, *p* = 0.015), and fungal sepsis OR 2.21 (95% CI 1.05--4.62, *p* = 0.035).

3.2. Multivariate Analysis {#sec3.2}
--------------------------

After adjusting for covariates, serum procalcitonin, OR 1.01 (95% CI 1.004--1.016) *p* = 0.002, SAPS II scores OR 1.01 (95% CI 1.004--1.02), *p* = 0.006, hematologic malignancy OR 3.3 (95% CI 1.4--7.4) *p* \< 0.004, fungal sepsis OR 2.7 (95% CI 1.2--5.8) *p* = 0.011, and MDR isolates OR 2.9 (95% CI 1.4--6.0) *p* = 0.003 remained significant predictors for no deescalation.

Please refer to [Table 4](#tab4){ref-type="table"} showing multivariate regression analysis to indicate variables associated with no deescalation of antimicrobials.

4. Discussion {#sec4}
=============

In this prospective study of critically ill, septic patients antimicrobial deescalation was carried out in less than half of all patients, with higher baseline procalcitonin levels, greater organ dysfunction scores, comorbid hematologic malignancy, isolation of drug-resistant bacteria, and fungal organisms identified as independent predictors of failure to deescalate.

The morbidity and costs of continued broad-spectrum antimicrobials and the safety of deescalation are now well established in the medical literature. A deescalation strategy has not been shown to be harmful in patients with varied immune statuses or systemic or limited infections or in fungal septicemia \[[@B7], [@B11], [@B10], [@B2]--[@B14]\] and in fact may even exert a protective effect as reported by Lee et al. \[[@B11]\] and Garnacho-Montero et al. \[[@B15]\].

Please see [Table 5](#tab5){ref-type="table"} for a summary of recent studies on antibiotic deescalation.

Despite reports of benefit, deescalation remains variably practiced with rates from 10 to 60% \[[@B16]\]. Please refer to [Table 5](#tab5){ref-type="table"}. In our cohort of multidisciplinary critically ill patients with sepsis and shock, antimicrobial deescalation was carried out in 48% patients, which is comparable to that reported by other investigators.

The real question then is when are physicians less likely to deescalate? Recent studies have shown that antibiotic deescalation becomes less likely with severe, complicated infections and drug-resistance and when initial antibiotic therapy is inadequate. Please refer to [Table 5](#tab5){ref-type="table"}. In our study, deescalation failure was predicted by the isolation of drug-resistant bacteria and fungal organisms, greater severity of illness as demonstrated by higher initial organ dysfunction scores, underlying hematologic malignancy, and a procalcitonin level that may suggest a greater bacterial load.

What then appears to be a common theme here is that physicians are uncomfortable deescalating antimicrobials when faced with sicker patients with a higher possibility of complications. Antimicrobial stewardship is a strategy that employs availability of either an infectious disease specialist and/or a clinical pharmacist to assist in decision-making at the bedside. Stewardship programs have been shown to successfully reduce resistance patterns, reduce antibiotic usage, and reduce costs without increasing adverse outcomes \[[@B27]--[@B34]\]. Our study confirms the results of others that there is a real need for and potential benefits of implementing antimicrobial stewardship programs across all areas where broad-spectrum antimicrobials are utilized. Whether they are specialty driven or pharmacy-led should be tailored to the resources available to individual centers.

This study\'s strengths are its large numbers of patients and the generalizability of our results to other ICUs. We have a varied case-mix from our surgical and medical ICUs with causative organisms that are similar to those isolated from most ICUs. The limitation of our results is that this is a single-center study.

Assisting the stewardship model is a recent publication from de Jong and colleagues \[[@B35]\] where, in a controlled trial in 15 Netherland hospitals, ICU admissions were randomized to usual care versus antibiotic deescalation once procalcitonin levels decreased by 80% or more of its peak value or to 0.5 *μ*g/L or lower. Mortality was significantly lower in the procalcitonin-guided group, between-group absolute difference 5.4% (95% CI 1.2--9.5, *p* = 0.0122). Therefore, procalcitonin absolute levels and patterns may assist bedside decision-making incorporated into an antibiotic stewardship program.

5. Conclusions {#sec5}
==============

Current deescalation practices reflect physician reluctance when dealing with complicated, sicker patients or with drug-resistance or fungal sepsis. Integrating an antibiotic stewardship program may increase physician confidence and provide support towards increasing deescalation rates.

The authors are indebted to Ahmed Kamal, MD, Assistant Consultant Adult Critical Care Medicine, KFSHRC, for his assistance in data collection.
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###### 

Characteristics of patients.

  Patient characteristics                     *n* = 395
  ------------------------------------------- -----------------------------
  APACHE II score                             24 ± 7.8
                                              
  Serum procalcitonin                         3.9 (IQR 25% 1.1, 75% 18.4)
                                              
  Admission during working hours              147 (37%)
  Admission after working hours               248 (63%)
                                              
  Vasopressors at 72 hours                    236 (60%)
                                              
  *Comorbid illnesses*                         
   Malignancy                                 86 (22%)
    Metastatic cancer                         26 (7%)
    Hematologic malignancy                    35 (9%)
   Acute respiratory failure                  67 (17%)
   Chronic renal failure                      64 (16%)
   Dialysis dependent                         42 (11%)
   Cirrhosis                                  62 (16%)
   Chronic diseases^*∗*^                      235 (59%)
                                              
  No microbial growth on admission cultures   200 (51%)
                                              
  *Source of sepsis*                           
   BSI                                        83 (42%)
   Respiratory                                72 (37%)
   Urinary tract                              27 (14%)
   Peritonitis                                11 (5%)
   Surgical site                              10 (5%)
                                              
  Multidrug resistant organisms               41 (21%)
                                              
  Fungal organisms                            36 (18%)
                                              
  Initial antimicrobial therapy appropriate   112 (57%)
                                              
  ICU length of stay (days)                   6 (IQR 39)
                                              
  ICU mortality                               74 (18.7%)
                                              
  28-day mortality                            114 (28.9%)

*∗* refers to chronic medical illnesses, that is, type 2 diabetes mellitus, coronary artery disease, and hypertension.

###### 

Frequencies of all microbial isolates.

  Organisms isolated               Number^⋆^
  -------------------------------- ------------
  *Enterobacteriaceae* ^*∗*^       57 (29.2%)
                                   
  *Pseudomonas aeruginosa*         53 (27.1%)
                                   
  *GPC* ^∧^                        21 (10.7%)
                                   
  *Fungal*                         25 (12.8%)
  *Candida albicans*               11 (5.6%)
  *Candida non-albicans*           13 (6.6%)
  *Aspergillus*                    1
                                   
  *Stenotrophomonas maltophilia*   8 (4%)
                                   
  *MRSA*                           7 (3.5%)
                                   
  *Acinetobacter baumannii*        7 (3.5%)
                                   
  *VRE*                            5 (2.5%)
                                   
  *Viruses* ^\#^                   3 (1.5%)
                                   
  *Miscellaneous* ^∧∧^             9 (16%)

^⋆^ *Out of 195 positive cultures*;  *∗* includes *Escherichia coli*, *Klebsiella*, *Enterobacter*, *Citrobacter koseri*, and *Proteus mirabilis*; ∧ includes *Streptococcus*sp. and methicillin-sensitive *Staphylococcus aureus*; \# includes MERS-corona, parainfluenza, and influenza; ∧∧ includes *Alcaligenes xylosoxidans*, *Vibrio cholerae*, *Mycobacterium tuberculosis*, and *Nocardia*.

###### 

Differences in patient characteristics by final antibiotic grouping.

  ------------------------------------------------------------------------------------------------------------------------------------------
                            Deescalation (*n* = 189)   No change (*n* = 156)   Escalation (*n* = 42)   Mixed changes (*n* = 8)   *p* value
  ------------------------- -------------------------- ----------------------- ----------------------- ------------------------- -----------
  SAPS II                   48 ± 19.5                  41 ± 19                 47 ± 18.5               44 ± 23.7                 0.007

  Admission procalcitonin   2.3\                       7.9\                    4.6\                    11.1\                     0.007
                            (IQR 0.7--7.4)             (IQR 2--33.6)           (IQR 1.1--11.1)         (IQR 7--15.3)             

  No growth                 86 (45.5%)                 102 (65.3%)             12 (28.5%)              0                         \<0.001

  Single site of sepsis     60 (31.7%)                 35 (22.4%)              22 (52.3%)              3 (37.5%)                 0.002

  MDR organism              12 (6.3%)                  22 (14.1%)              5 (11.9%)               2 (25%)                   0.05

  Fungal sepsis             11 (5.8%)                  15 (9.6%)               8 (19%)                 2 (25%)                   0.019

  ICU length of stay        6.5\                       5.5\                    5\                      7.5\                      0.003
                            (IQR 4.2--44)              (IQR 4--17)             (IQR 4--36.5)           (IQR 5--33.2)             

  ICU mortality             28 (14.8%)                 38 (24.4%)              6 (14.3%)               2 (25%)                   0.11
  ------------------------------------------------------------------------------------------------------------------------------------------

###### 

Multivariate regression analysis to indicate variables associated with no deescalation of antimicrobials.

                            Wald statistic   Exp(*B*)   95% CI for Exp(*B*)   *p* value   
  ------------------------- ---------------- ---------- --------------------- ----------- -------
  Hematologic malignancy    8.31             3.30       1.46                  7.44        0.004
  Admission procalcitonin   9.73             1.01       1.004                 1.016       0.002
  Fungal sepsis             6.50             2.70       1.25                  5.80        0.011
  MDR organisms isolated    8.58             2.94       1.43                  6.07        0.003
  SAPS II score             7.59             1.01       1.004                 1.026       0.006

###### 

Summary of studies on antibiotic deescalation.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                             Study type                           Setting                                                              Patients                                       Deescalation rate   Association with outcomes                                                                                                                                                         Factors associated with no deescalation
  ------------------------------------------ ------------------------------------ -------------------------------------------------------------------- ---------------------------------------------- ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Rello et al., 2004 \[[@B17]\]              Prospective, observational           Medical-surgical ICU with VAP                                        115                                            31.4%               Not reported                                                                                                                                                                      Nonfermenting Gram-negative bacillus (2.7% versus 49.3%), late-onset pneumonia (12.5% versus 40.7%), *p* \< 0.05

                                                                                                                                                                                                                                                                                                                                                                                                            

  Eachempati \                               Observational                        Surgical ICU with VAP                                                138                                            55%                 No difference in recurrent pneumonia rate or mortality, 34% versus 42%                                                                                                            Not reported
   et al., 2009 \[[@B18]\]                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                            

  De Waele et al., 2010 \[[@B19]\]           Retrospective                        Surgical ICU                                                         113                                            42%                 No difference in mortality rate (7% versus 21%, *p* 0.12)                                                                                                                         Negative cultures, colonization with multiresistant Gram-negative organisms

                                                                                                                                                                                                                                                                                                                                                                                                            

  Hibbard et al., 2010 \[[@B20]\]            Retrospective                        Surgical ICU, VAP                                                    811 antibiotic days                            78%--59%            No change in resistance rates                                                                                                                                                     Not reported

                                                                                                                                                                                                                                                                                                                                                                                                            

  Morel et al., 2010 \[[@B21]\]              Retrospective                        Mixed ICU                                                            116                                            45%                 Recurrent infection (19% versus 5%, *p*  0.01)                                                                                                                                    Inadequate empiric antibiotic and initial therapy not containing aminoglycoside

                                                                                                                                                                                                                                                                                                                                                                                                            

  Gonzalez et al., 2013 \[[@B7]\]            Retrospective                        Medical ICU                                                          229                                            51%                 No differences in mortality, length of stay, antibiotic duration, mechanical ventilation, ICU-acquired infection, or drug-resistant bacteria                                      Inadequacy of initial antibiotic therapy (OR = 0.1, 0.0 to 0.1, *p* \< 0.001), multidrug resistant bacteria (OR = 0.2, 0.1 to 0.7, *p* = 0.006)

                                                                                                                                                                                                                                                                                                                                                                                                            

  Duchêne et al., 2013 \[[@B22]\]            Retrospective                        Urosepsis                                                            80                                             46%                 Not reported                                                                                                                                                                      Shock, renal abscess, obstructive uropathy, bacterial resistance

                                                                                                                                                                                                                                                                                                                                                                                                            

  Garnacho-Montero et al., 2014 \[[@B15]\]   Prospective, observational           Medical                                                              712                                            34.9%               Deescalation protective for mortality (OR 0.54; 95% CI 0.33-0.89)                                                                                                                 Not reported

                                                                                                                                                                                                                                                                                                                                                                                                            

  Carugati et al., 2015 \[[@B23]\]           Secondary analysis of CAP database   Medical with CAP                                                     261                                            63.2%               No association with mortality                                                                                                                                                     More severe presentation

                                                                                                                                                                                                                                                                                                                                                                                                            

  Lee et al., 2015 \[[@B11]\]                Retrospective                        Community-onset monomicrobial Enterobacteriaceae (CoME) bacteremia   189                                            45.5%               Deescalation strategy was protective for mortality (OR 0.37, *p* 0.04)                                                                                                            Not reported

                                                                                                                                                                                                                                                                                                                                                                                                            

  Madaras-Kelly et al., 2016 \[[@B10]\]      Retrospective                        HCAP in VA system                                                    9319                                           28.3%               Not reported                                                                                                                                                                      Deescalation associated with initial broad-spectrum therapy (OR 1.5, 95% CI 1.4--1.5), collection of respiratory tract cultures (OR 1.1, 95% CI 1.0--1.2), care in higher complexity facilities (OR 1.3, 95% CI 1.1--1.6)

                                                                                                                                                                                                                                                                                                                                                                                                            

  Falguera et al., 2010 \[[@B24]\]           RCT                                  Community-acquired pneumonia                                         177, deescalation by urinary antigen results   ---                 Higher cost (*p* 0.28), reduced adverse events (9% versus 18%, *p* 0.12), lower exposure to broad-spectrum antimicrobials (154.4 versus 183.3 daily doses per 100 patient days)    

                                                                                                                                                                                                                                                                                                                                                                                                            

  Kim et al.,  2012 \[[@B25]\]               RCT                                  Medical ICU, hospital-acquired pneumonia                             109                                            ---                 No differences in ICU stay or mortality rates, higher risk of MRSA with deescalation; HR 3.84; 95% CI 1.06--13.91                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                            

  Leone et al., 2014 \[[@B26]\]              Multicenter, RCT                     Severe sepsis                                                        60                                             ---                 Deescalation resulted in prolonged duration of ICU stay; mean difference 3.4 (95% CI −1.7--8.5); no effect on mortality                                                           Not reported
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ICU: intensive care unit; VAP: ventilator-associated pneumonia; CAP: community-acquired pneumonia; HCAP: healthcare associated pneumonia; HR: hazard ratio; OR: odds ratio.
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